NASDAQ:GNCA - Genocea Biosciences Stock Price, Forecast & News

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

Genocea Biosciences Inc (NASDAQ:GNCA) issued its quarterly earnings results on Thursday, February, 13th. The biotechnology company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.05. View Genocea Biosciences' Earnings History.

Genocea Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Genocea Biosciences.

5 equities research analysts have issued twelve-month price objectives for Genocea Biosciences' stock. Their forecasts range from $7.00 to $32.00. On average, they anticipate Genocea Biosciences' stock price to reach $16.33 in the next twelve months. This suggests a possible upside of 674.1% from the stock's current price. View Analyst Price Targets for Genocea Biosciences.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genocea Biosciences.

Media coverage about GNCA stock has been trending neutral on Tuesday, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Genocea Biosciences earned a media sentiment score of 0.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the company's share price in the next several days. View News Stories for Genocea Biosciences.

Genocea Biosciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 118,300 shares, an increase of 21.3% from the January 15th total of 97,500 shares. Based on an average daily volume of 160,700 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.8% of the company's stock are sold short. View Genocea Biosciences' Current Options Chain.

Some companies that are related to Genocea Biosciences include Verona Pharma (TARA), CASI Pharmaceuticals (CASI), ADMA Biologics (ADMA), LogicBio Therapeutics (LOGC), Jounce Therapeutics (JNCE), Windtree Therapeutics (WINT), Fennec Pharmaceuticals (FENC), Dyadic International (DYAI), Solid Biosciences (SLDB), Erytech Pharma (ERYP), Brainstorm Cell Therapeutics (BCLI), Gamida Cell (GMDA), X4 Pharmaceuticals (XFOR), Axcella Health (AXLA) and Cidara Therapeutics (CDTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO).

Genocea Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.07%), FNY Investment Advisers LLC (1.05%), Wedbush Securities Inc. (0.07%), Virtu Financial LLC (0.07%) and Oxford Asset Management LLP (0.05%). Company insiders that own Genocea Biosciences stock include George Siber, Michael Alfieri and Peter W Sonsini. View Institutional Ownership Trends for Genocea Biosciences.

GNCA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FNY Investment Advisers LLC, Wedbush Securities Inc., Virtu Financial LLC and Oxford Asset Management LLP. Company insiders that have bought Genocea Biosciences stock in the last two years include George Siber, Michael Alfieri and Peter W Sonsini. View Insider Buying and Selling for Genocea Biosciences.

Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GNCA stock can currently be purchased for approximately $2.11.

Genocea Biosciences has a market capitalization of $55.18 million. The biotechnology company earns $-38,950,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Genocea Biosciences employs 61 workers across the globe.View Additional Information About Genocea Biosciences.

The official website for Genocea Biosciences is http://www.genocea.com/.

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]